Tomas Stulc

Tomas Stulc

Auto-generated profile, based on publicly available information

Tomas Stulc

Third Department of Internal Medicine, Charles University, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2000 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SCSusanne M. Clee
Susanne M. Clee
JKJohn J.P. Kastelein
John J.P. Kastelein
MDMarjel van Dam
Marjel van Dam
MMMichel Marcil
Michel Marcil
KRKirsten Roomp
Kirsten Roomp
MHMichael R. Hayden
Michael R. Hayden
We and others have recently identified mutations in the ABCA1 gene as the underlying cause of Tangier disease (TD) and of a dominantly inherited form of familial hypoalphalipoproteinemia (FHA) associated with reduced cholesterol efflux. We have now identified 13 ABCA1 mutations in 11 families (five TD, six FHA) and have examined the phenotypes of 77 individuals heterozygous for mutations in the ABCA1 gene. ABCA1 heterozygotes have decreased HDL cholesterol (HDL-C) and increased triglycerides. Age is an important modifier of the phenotype in heterozygotes, with a higher proportion of heterozygotes aged 30–70 years having HDL-C greater than the fifth percentile for age and sex compared with carriers less than 30 years of age. Levels of cholesterol efflux are highly correlated with HDL-C levels, accounting for 82% of its variation. Each 8% change in ABCA1-mediated efflux is predicted to be associated with a 0.1 mmol/l change in HDL-C. ABCA1 heterozygotes display a greater than threefold increase in the frequency of coronary artery disease (CAD), with earlier onset than unaffected family members. CAD is more frequent in those heterozygotes with lower cholesterol efflux values. These data provide direct evidence that impairment of cholesterol efflux and consequently reverse cholesterol transport is associated with reduced plasma HDL-C levels and increased risk of CAD.

1 December 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
Maciej BanachMaciej Banach
Maciej Banach
TSTomas Stulc
Tomas Stulc
RDRicardo Dent
Ricardo Dent
PTPeter P. Toth
Peter P. Toth

21 October 2015 in Current Atherosclerosis Reports
Verified
Journal Article
Open access
PDF file
TSTomáš Stulc
Tomáš Stulc
RCRichard Ceška
Richard Ceška
AGAntonio M. Gotto
Antonio M. Gotto
Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.

1 May 2010 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
TSTomas Stulc
Tomas Stulc
ASAleksi Sedo
Aleksi Sedo

1 June 2004 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JŠJan Škrha
Jan Škrha
TŠTomáš Štulc
Tomáš Štulc
JHJiřina Hilgertová
Jiřina Hilgertová
HWHana Weiserová
Hana Weiserová
JKJan Kvasnička
Jan Kvasnička
RČRichard Češka
Richard Češka

1 September 2001 in Nutrition
Verified
Journal Article
Closed access
TŠTomáš Štulc
Tomáš Štulc
VMVojtěch Melenovský
Vojtěch Melenovský
BGBarbora Grauová
Barbora Grauová
VKViktor Kožich
Viktor Kožich
RČRichard Češka
Richard Češka